Clinical Trials Logo

Clinical Trial Summary

This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or standard second-line chemotherapy, with 1:1 random ratio.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

NCT number NCT04385550
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Ruihua Xu
Phone 020-87343468
Email ruihxu@163.com
Status Not yet recruiting
Phase Phase 3
Start date May 20, 2020
Completion date December 31, 2023